CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 6,686	$ 6,352
Costs and expenses:
Cost of goods sold	1,552	1,401
Research and development expenses	1,520	1,447
Acquired in-process research and development expenses	4,131	481
In-process research and development impairment	2,430	0
Selling, general and administrative expenses	1,375	1,319
Total costs and expenses	11,008	4,647
Operating (loss) income	(4,322)	1,705
Interest expense	254	230
Other (income) expense, net	(91)	174
(Loss) income before income taxes	(4,486)	1,300
Income tax (benefit) expense	(315)	316
Net (loss) income	(4,170)	985
Net loss attributable to noncontrolling interest	0	(26)
Net (loss) income attributable to Gilead	$ (4,170)	$ 1,010
Basic (loss) earnings per share attributable to Gilead (in dollars per share)	$ (3.34)	$ 0.81
Shares used in basic (loss) earnings per share attributable to Gilead calculation (in shares)	1,247	1,248
Diluted (loss) earnings per share attributable to Gilead (in dollars per share)	$ (3.34)	$ 0.80
Shares used in diluted (loss) earnings per share attributable to Gilead calculation (in shares)	1,247	1,261
Product sales
Revenues:
Total revenues	$ 6,647	$ 6,306
Royalty, contract and other revenues
Revenues:
Total revenues	$ 39	$ 46